Phase I Study of HBT-708 for Patients With Advanced Solid Tumors

This study is a study of HBT-708 monotherapy in advanced solid tumors. This study includes dose-escalation and dose-expansion cohort, with the accelerated titration combined 3+3 dose escalation method. The administration frequencies of HBT-708 is Q3W i.v. All cohorts will assess the efficacy and safety of the preset several dose levels of HBT-708 in advanced solid tumors.

Inclusion criteria

• Male or female subjects, age 18 years or older.
• Histologically and/or cytologically documented advanced or measurable solid tumors.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
• Life expectancey > = 3 months.
• Willingness to provide written informed consent for the study.

Exclusion criteria

• Known uncontrolled or symptomatic central nervous system metastatic disease.
• Subjects must have recovered (≤ Grade 1 or pretherapy baseline) from AEs due to previously administered therapies. (National Cancer Institute Common terminology Criteria [NCI CTCAE] v.5.0).
• Inadequate organ or bone marrow function.
• Pregnant or breast-feeding woman.
• Known allergies, hypersensitivity, or intolerance to HBT-708 The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.